Publications

Found 6 results
Filters: Author is Chan, Albert H and First Letter Of Title is S  [Clear All Filters]
2025
Dharmaiah, S., Bonsor, D. A., Mo, S. P., Fernandez-Cabrera, A., Chan, A. H., Messing, S., Drew, M., Vega, M., Nissley, D. V., Esposito, D., Castel, P., and Simanshu, D. K. (2025) Structural basis for LZTR1 recognition of RAS GTPases for degradation. Science. 389, 1112-1117
2022
Frey, K. M., Bertoletti, N., Chan, A. H., Ippolito, J. A., Bollini, M., Spasov, K. A., Jorgensen, W. L., and Anderson, K. S. (2022) Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase. Front Mol Biosci. 9, 805187
2020
Duong, V. N., Ippolito, J. A., Chan, A. H., Lee, W. - G., Spasov, K. A., Jorgensen, W. L., and Anderson, K. S. (2020) Structural investigation of 2-naphthyl phenyl ether inhibitors bound to WT and Y181C reverse transcriptase highlights key features of the NNRTI binding site. Protein Sci. 10.1002/pro.3910
2019
Kudalkar, S. N., Ullah, I., Bertoletti, N., Mandl, H. K., Cisneros, J. A., Beloor, J., Chan, A. H., Quijano, E., W Saltzman, M., Jorgensen, W. L., Kumar, P., and Anderson, K. S. (2019) Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV. Antiviral Res. 167, 110-116
Bertoletti, N., Chan, A. H., Schinazi, R. F., Y Yin, W., and Anderson, K. S. (2019) Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. Protein Sci. 28, 1664-1675
2017
Kudalkar, S. N., Beloor, J., Chan, A. H., Lee, W. - G., Jorgensen, W. L., Kumar, P., and Anderson, K. S. (2017) Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection. Mol Pharmacol. 91, 383-391